BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37945383)

  • 21. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
    Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
    Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
    Behr TM; Béhé MP
    Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo.
    Holzleitner N; Günther T; Beck R; Lapa C; Wester HJ
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
    Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
    Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [
    Grzmil M; Qin Y; Schleuniger C; Frank S; Imobersteg S; Blanc A; Spillmann M; Berger P; Schibli R; Behe M
    Theranostics; 2020; 10(24):10861-10873. PubMed ID: 33042258
    [No Abstract]   [Full Text] [Related]  

  • 27. Substitution of l-Tryptophan by
    Günther T; Deiser S; Felber V; Beck R; Wester HJ
    J Nucl Med; 2022 Sep; 63(9):1364-1370. PubMed ID: 35027371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
    Nock BA; Maina T; Krenning EP; de Jong M
    J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
    Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Sinnes JP; Bauder-Wüst U; Schäfer M; Moon ES; Kopka K; Rösch F
    EJNMMI Radiopharm Chem; 2020 Nov; 5(1):28. PubMed ID: 33242189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies.
    von Guggenberg E; Rangger C; Sosabowski J; Laverman P; Reubi JC; Virgolini IJ; Decristoforo C
    Mol Imaging Biol; 2012 Jun; 14(3):366-75. PubMed ID: 21732165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Evaluation of
    Ganguly T; Bauer N; Davis RA; Foster CC; Harris RE; Hausner SH; Roncali E; Tang SY; Sutcliffe JL
    J Nucl Med; 2023 Apr; 64(4):639-644. PubMed ID: 36207137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
    Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
    Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
    J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
    Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of PET/CT imaging with [
    Uprimny C; von Guggenberg E; Svirydenka A; Mikołajczak R; Hubalewska-Dydejczyk A; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):935-936. PubMed ID: 32748048
    [No Abstract]   [Full Text] [Related]  

  • 37.
    Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
    Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
    [No Abstract]   [Full Text] [Related]  

  • 38. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
    Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
    J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.